Podofilox-induced regression of Shope papillomas may be independent of host immunity.
We tested the hypothesis that infiltrating leukocytes might contribute to papilloma destruction following podofilox treatment. New Zealand White (NZW) rabbits were inoculated with cottontail rabbit papillomavirus (CRPV) onto abraded areas of the dorsal skin. At 21 d after viral inoculation, 5.0% podofilox solution was applied to some papillomas, whereas others were used as controls. Three rabbits were sacrificed at each of three different periods after treatment initiation (1, 4, and 7 d). Four monoclonal antibodies (MoAbs), RG-16 (for B cells), L11/135 (specific for T cells), 2C4 (specific for class II antigen), and Ki67 (specific for proliferating cells), were used in an immunohistochemical study. All positive cells and total cells in the field were counted with an ocular grid. After 1 d of treatment, proliferation of papilloma cells was strongly suppressed in treated papillomas, but leukocytic infiltration was not altered. At 4 d and 7 d of treatment, there were substantial increases (about two to three times) in the numbers of B and T cells and class II-expressing leukocytes. The upper layers of the papillomas were highly necrotic and cell proliferation was absent in all layers. These data support the view that podofilox has a direct toxic effect on papilloma tissue. Leukocyte infiltration is not strongly associated with papilloma tissue and may not contribute to papilloma destruction.
Okabayashi
M
M
Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Pickel
M D
MD
Budgeon
L R
LR
Cladel
N M
NM
Kreider
J W
JW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001402:B-Lymphocytes / Q000166:cytology; D002471:Cell Transformation, Neoplastic; D012777:Cottontail rabbit papillomavirus; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007109:Immunity; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis; D009687:Nuclear Proteins / Q000032:analysis; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000276:immunology*; D011034:Podophyllotoxin / Q000627:therapeutic use*; D011817:Rabbits; D012867:Skin / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011034:Podophyllotoxin